Target : Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after successful left atrial appendage closure (LAAC). The aim is to investigate whether rivaroxaban could provide correct anticoagulation levels and adequately suppress coagulation activation after LAAC

Trial date : 2017

Number of patients : 90

Source of funding : Public (APHP) & Private (Bayer)

Centers participating : Multicenter national trial

N°NCT : NCT03273322